Clinical trials: Pancreas Tumor
Pancreatic Trauma, Pancreatic Duct Injury
A Retrospective Analysis of Pancreatic Injuries and Treatment Outcomes
The goal of this observational study is to compare the presentation, treatment, and outcomes in patients suffering traumatic pancreatic injuries from blunt or penetrating trauma. The questions this study aims to answer are: 1.
- Conditions
- Pancreatic Trauma, Pancreatic Duct Injury, Pancreas Necrosis, Pancreas Cyst
- Trial name
- NCT06227871
- Testing
- Exploratory laparotomy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kern Medical Center
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University
Breast Cancer, Colorectal Cancer
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT00369109
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Neuroendocrine Tumors
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal…
- Trial name
- NCT03279601
- Testing
- Capecitabine, Dacarbazine, Capecitabine, Temozolomide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Peking University
Cancer Pain
Coeliac Plexus Neurolysis Versus Splanchnic Nerve Neurolysis
Pain is prevalent among patients with gastrointestinal cancers. Standard procedures such as coeliac plexus neurolysis (CPN) is effective in reducing pain, opioid requirement and related side effects for pancreatic cancer cases.
- Trial name
- NCT05541211
- Testing
- Coeliac plexus neurolysis, Splanchnic nerve neurolysis
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery.
- Trial name
- NCT01065870
- Testing
- Neoadjuvant gemcitabine, capecitabine, and docetaxel, Gemcitabine, capecitabine, docetaxel followed by radiotherapy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Columbia University
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
This phase II trial is studying how well giving radiation therapy together with oxaliplatin and fluorouracil followed by gemcitabine works in treating patients with locally advanced, unresectable pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00096070
- Testing
- radiation therapy, oxaliplatin, fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
- Trial name
- NCT06199466
- Testing
- Gemcitabine, Nab-paclitaxel, YL-13027
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Carcinoma
A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma.
- Trial name
- NEOPAN (NCT02539537)
- Testing
- Gemcitabine, Folinic Acid, 5-Fluoro-uracil
- Where
- 45 sites in France
- Volunteers
- 171 people
- Sponsor
- UNICANCER
Overall Survival
Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an investigational drug of Anlotinib (a small molecular anti-VEGF TKI) with PD-1 inhibitor in second-line therapy with the goal of…
- Trial name
- NCT05218629
- Testing
- Anlotinib, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
Untreated, Advanced Pancreatic Cancer
A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.
Phase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer.
- Trial name
- NUMANTIA-2 (NCT07578337)
- Testing
- Gemcitabine (1000 mg/m2), Nab-paclitaxel (Abraxane), NLM-001
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Nelum Corp
Pancreatic Cancer
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer.
- Trial name
- NCT00652366
- Testing
- Erlotinib, escalating dose, Erlotinib, standard dose, Gemcitabine
- Where
- 89 sites in Argentina, Australia and 21 more
- Volunteers
- 467 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Adenocarcinoma
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
This is an open label, single institution, dose-escalation phase 1 study designed to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled…
- Trial name
- PANC-001 (NCT04270929)
- Testing
- FOLFIRI, FOLFIRINOX, TriSalus Infusion System
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Metastatic Pancreatic Cancer
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients…
- Trial name
- NCT06532331
- Testing
- ONO-7475, ONO-4538, Nab-paclitaxel
- Where
- 9 sites in Japan
- Volunteers
- 87 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic…
- Trial name
- PROBE (NCT07825753)
- Testing
- Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Fudan University
Pancreas Cancer
International CAPS Registry: Pancreas Cancer Cases in Surveillance Programs
Various centers around the world are currently investigating the feasibility and yield of surveillance for pancreatic cancer in high-risk individuals.
- Trial name
- CAPS Registry (NCT02703545)
- Volunteers
- 58 people
- Sponsor
- Johns Hopkins University
Pancreatic Cancer
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
To learn if a supervised exercise program during chemotherapy treatments can help to improve outcomes in patients who have been diagnosed with pancreatic cancer
- Trial name
- NCT05836870
- Testing
- Enhanced Usual Care, Tele-supervised resistance exercises
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Tumor
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
- Trial name
- PACAomics (NCT01692873)
- Testing
- suspected pancreatic tumor
- Where
- France
- Volunteers
- 274 people
- Sponsor
- Institut Paoli-Calmettes
Metastatic Pancreatic Cancer
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in slowing tumor activity in patients with metastatic pancreatic cancer who have previously received 1st line treatment with a gemcitabine…
- Trial name
- NCT00652054
- Testing
- S-1
- Volunteers
- 39 people
- Sponsor
- Taiho Oncology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.